Form 4: Aurinia Pharmaceuticals Director Kathleen Goetz Acquires Stock Options

Kathleen Goetz, a director of Aurinia Pharmaceuticals, was granted stock options to purchase 63,724 common shares on May 16, 2025, exercisable after one year.

Summary

• Kathleen Goetz, a director of Aurinia Pharmaceuticals Inc., filed a Form 4 on May 16, 2025.
• The filing reports the grant of stock options, representing the right to buy 63,724 common shares.
• The exercise price of the options is $8.15 per share.
• The options vest one year from the grant date, on May 16, 2026, and expire on May 16, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options could be viewed as mildly positive, indicating confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of directors and management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• The size of the grant (63,724 shares) would need to be compared to grants made to directors at comparable companies (e.g., other pharmaceutical companies with similar market capitalization and stage of development) to assess its relative magnitude.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, Form 4, director, Aurinia Pharmaceuticals, AUPH, Kathleen Goetz, beneficial ownership